New hope for tough breast cancers: immune drug plus radiation shows promise

This study is for people with HER2-negative breast cancer whose tumors did not shrink after the first round of chemotherapy. It tests whether adding an immunotherapy drug called toripalimab, sometimes with targeted radiation, can improve outcomes before and after surgery. About 110 participants will be split into groups to compare standard chemo alone versus chemo plus toripalimab, with or without radiation. The goal is to see if these combinations can eliminate more cancer cells before surgery.